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I N S T R U C T I O N S T O A U T H O R S
The Journal considers any original research that 
advocates change in, or illuminates, clinical practice. The 
journal also publishes interesting and informative reviews 
and opinion pieces on any topic connected with clinical 
practice. Manuscripts must be solely the work of the 
author(s) stated, not have been published previously 
elsewhere, and not be under consideration by another 
journal. All papers should be written to be clearly 
understandable to the journal's readers in a wide range of 
specialties and countries. Diagrams, figures, and 
photographs should be used to supplement and enhance 
the text.
Article of Research Journal, with writing structure:
?Title of the article 
Author name and address of related institution 
(The name and address of the corresponding 
author should be separately and clearly 
indicated, together with email and telephone 
details)
?Abstract in English version, at least consist of 250 
words 
?Key words: that identify abstract, consist of 3 – 10 
key words or short phrases.
?Introduction (without subtitle, state the rationale 
for the study some references and main problem / 
the study purpose)
?Methods
Results
?Discussion
Conclusion 
?References (consist of references of minimal 10 
years recently and in the form of essay).
The articles are sent to the secretariat in the form 
of 3 copies of print-out article and file in disk. Articles may 
also be sent by email to actainterna@yahoo.com. The 
article must be original, never being publicized, and will 
not submitted to other publisher. It must be written in 
English. Articles are written on letter pages, double space, 
with left and right border of 3 cm respectively.
Article of Reference, with writing structure:
?Title of the article
Author name and address of related institution 
(The name and address of the corresponding 
author should be separately and clearly 
indicated, together with email and telephone 
details)
?Introduction (without subtitle, state the rationale 
for the study some references and main problem / 
the study purpose, maximal 1 page)
?Subtitle (in keeping with needs)
Subtitle (in keeping with needs)
?Subtitle (in keeping with needs)
Conclusion 
?References (consist of references of minimal 10 
years recently and in the form of essay).
Article of Case Report contains:
?Title
Author name and address of related institution 
(likely, address and telephone number/mobile 
phone correspondence that can be contacted 
anytime should be attached)
?Introduction (without subtitle, state the rationale 
for the study some references and main problem / 
the study purpose, maximal 1 page)
?Case report / Case Illustration 
Discussion
?Conclusion
References (consist of references of minimal 10 years 
recently and in the form of essay).
Title Page and Author
Title page should consist of: (1) Title of the article (2) 
Complete name and profession title (3) Institution Name 
(4) Address of correspondence of main author. 
Notes:
Illustration
Illustration, which is enclosed in the article can be hand-
made picture, photograph, table or graph. Hand-made 
picture are made by black ink on white paper. Photograph 
can be enclosed in the article or as a file of scan result. 
Tables are made complete, including the parts of: 
?table number; 
table title; 
?explanations; and 
data in the form of number. Graphic is made by 
appropriate scale to the real numbers.
Ethics
In reporting / writing experiments result with certain object 
(i.e. patient's names, or institution or others), should never 
mention about identity or other characteristic that 
describes that object. The Editorial Board reserves the 
right to carry out editorial change if it is considered 
important.
E D I T O R I A L N O T E
1
CLINICAL CHARACTERISTICS AND DISEASE SEVERITY
Caring patients with chronic illnesses or 
acute severe diseases often drives physicians to 
find clinical characters that may predict 
outcome or describe severity of disease. Sorting 
patients with poorer prognosis or with 
particular risk factors will facilitate application 
of aggressive treatment in this high risk group 
of patients. 
ndIn this 2  edition of Acta Interna, we 
include 4 original articles that explore the 
certain clinical characteristic related to severity 
of disease; 1 original article related to particular 
side effect of cancer chemotherapy; and one 
case report of complication of chronic end stage 
disease.  
One art icle from gastroentero 
hepatology highlighted correlation of Cystatin 
C, a non-glycosylated protein of 13 kDa 
cystatin super family, in severity of cirrhosis. 
Cystatin C- which is recommended to assess 
declining of renal function- is correlated with 
severity of cirrhosis (which is measured by 
Model of End Stage Liver Disease [MELD]). 
MELD itself has been commonly used to 
measure severity of cirrhosis patients using 
calculation of 3 clinical characters of serum 
creatinin, total bilirubin, and INR. In this study 
higher serum Cystatin C level was correlated 
with higher MELD score or more severe 
condition. The second original article came 
from cardiology area. This study correlated 
serum level of Matrix Metalloproteinase-9 
(MMP-9), an extracellular matrix degrading 
enzyme, with severity of muscle damage in 
acute coronary syndrome which was measured 
with serum Troponin-I level. Some clinical 
characteristics failed to be proved to have 
significant role in assessing disease severity as 
reported by our third article from pulmonology, 
which could not prove the role of serum 
magnesium level in predicting severity of 
asthma measured with Peak Expiratory Flow. 
thOur 4  article reported that higher level of 
potassium on admission and neurological 
symptoms were associated with mortality in 
Leptospirosis. However, all these four original 
articles used cross sectional design and 
retrospective studies which owned limitation in 
drawing conclusion.
We involved another original article 
from hemato-oncology area reporting 
significant declining of cognitive function 
among breast cancer women received 
antracyclin based adjuvant chemotherapy. A 
case report of a chronic kidney disease patient 
experienced complication of acute coronary 
syndrome despite of undergone routine 
hemodialysis captured quality of care and the 
role of secondary prevention approach in 
chronic disease management. This case report 
ndwill close our 2  edition.
Sincerely Yours,
        Editors
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and C than Child A. There was no significant 
difference in cystatin C levels between Child B and 
C. A decline in renal function can already be found 
in Child A liver cirrhosis, although the results were 
26not statistically significant . The mean cystatin C 
was higher in patients with decompensated cirrhosis 
than compensated ones. Cystatin C is an excellent 
marker in assessing in the GFR and should be added 
as a routine examination of patients with cirrhosis of 
27the liver to assess renal abnormalities .
Correlation test of cystatin C to score of 
MELD was significant with medium strength, with 
p=0.000 and r=0.485. The strength of this 
correlation is influenced by the distribution of 
subjects according to score of MELD which is 
relatively not even with MELD <10, 13 subjects 
(27.1%); MELD 10-19, 29 subjects (60.4%), 
MELD 20-29, four subjects (8.3%); and MELD 30-
39 and > 40 respectively 1 subjects (2.1%). The 
result of linear regression showed that elevated 
levels of cystatin C were associated with increased 
severity of the liver, meaning that the greater the 
score of MELD the greater the level of cystatin C. 
The severity of circulatory dysfunction has 
been reported to be associated with the severity of 
28liver cirrhosis . It was found that only score of 
MELD associated with cystatin C. Cystatin C levels 
between group score of MELD was significantly 
different. Score of MELD indicates the severity of 
liver cirrhosis, which also can be interpreted as 
circulation dysfunction. Severe circulatory 
dysfunction will eventually affect renal function as 
indicated by decrease in GFR. Decrease in GFR can 
be measured by an increase in cystatin C. Sex, age, 
albumin and ascites was not associated with 
increased levels of cystatin C or decreased renal 
function.
This study has several limitations. First, this 
study uses cross-sectional research design. Cross 
sectional study does not describe the course of the 
disease because of exposure and outcome measured 
at the same time so that no causal conclusion can be 
drawn. This can lead to bias due to existing data only 
describe the current state of research. Second, the 
distribution of subjects per group MELD scores was 
not even and thus affected the strength of correlation 
of cystatin C with a score of MELD. Third, although 
we have tried to control some possible disturbing 
factors that can affect cystatin C still there are 
several factors affecting levels of cystatin C which 
are not fully controlled, such as an increase or 
decrease in thyroid function (TSH and free T4 
levels), the use of steroids high dose and the 
presence of malignancy (melanoma and colorectal 
cancer). Further research needs to be done with the 
design of case control or cohort study to find out 
whether cystatin C could be used as predictor of 
severity of liver cirrhosis.
CONCLUSION
There is a correlation between cystatin C 
levels with the degree of severity of liver cirrhosis 
according to score of MELD with medium strength. 
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